Moderna Inc (MRNA)
Liquidity ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 3.67 | 4.39 | 4.09 | 4.03 | 3.42 | 2.46 | 3.39 | 3.46 | 2.73 | 2.10 | 1.99 | 1.77 | 1.76 | 1.35 | 1.24 | 1.39 | 1.43 | 2.43 | 17.30 | 9.29 |
| Quick ratio | 3.18 | 3.12 | 3.59 | 3.58 | 2.85 | 1.73 | 2.71 | 2.55 | 2.01 | 1.23 | 1.16 | 1.09 | 1.18 | 0.89 | 0.90 | 0.92 | 1.05 | 2.22 | 16.81 | 9.05 |
| Cash ratio | 3.18 | 3.12 | 3.59 | 3.58 | 2.85 | 1.73 | 2.71 | 2.55 | 2.01 | 1.23 | 1.16 | 1.09 | 1.18 | 0.89 | 0.90 | 0.92 | 1.05 | 2.22 | 16.81 | 9.05 |
Based on the provided data, let's analyze the liquidity ratios of Moderna Inc over the different quarters:
1. Current Ratio:
- The current ratio is a measure of a company's ability to cover its short-term liabilities with its short-term assets. A current ratio above 1 indicates that a company has more current assets than current liabilities.
- For Moderna Inc, the current ratio has shown some fluctuations over the quarters, ranging from as high as 17.30 in June 2020 to as low as 1.24 in June 2021.
- The company's current ratio generally trended downwards from 2020 to 2021 but showed improvement in 2022 and 2023, reaching 4.09 in June 2024, indicating a stronger ability to cover short-term obligations.
2. Quick Ratio:
- The quick ratio, also known as the acid-test ratio, is a more stringent measure of liquidity that excludes inventory from current assets.
- Moderna Inc's quick ratio generally followed a similar trend to the current ratio, ranging from a high of 16.81 in June 2020 to a low of 0.89 in September 2021.
- The quick ratio also saw improvements in later quarters, reaching 3.59 in June 2024, reflecting a stronger ability to cover short-term liabilities without relying on inventory.
3. Cash Ratio:
- The cash ratio is the most conservative liquidity ratio, focusing solely on a company's ability to cover its current liabilities with cash and cash equivalents.
- Moderna Inc's cash ratio mirrored the trends seen in the quick ratio, with fluctuations over the quarters and improvements in later periods.
- The cash ratio increased from 0.90 in June 2021 to 3.59 in June 2024, suggesting the company maintained a healthy level of cash reserves relative to its short-term obligations.
In conclusion, Moderna Inc's liquidity ratios have shown variability over the quarters, but there have been notable improvements in the company's ability to cover short-term liabilities with its current assets, especially in the later periods leading up to June 2024.
See also:
Additional liquidity measure
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash conversion cycle | days | 27.71 | 86.87 | 42.12 | 26.70 | 15.71 | 31.28 | 57.47 | 51.47 | 63.96 | 170.36 | 172.19 | 206.00 | 200.98 | 210.54 | 181.24 | 258.72 | 27.72 | 0.00 | 0.00 | 0.00 |
The cash conversion cycle of Moderna Inc has shown fluctuations over the quarters. It started at 0.00 days in March and June 2020, indicating that the company was able to convert its inventory into cash quickly. However, from December 2020 to March 2021, the cash conversion cycle increased significantly to 258.72 days, which suggests a longer period to turn inventory into cash.
Subsequently, there were fluctuations in the cash conversion cycle, with peaks in March and September 2021 at 210.54 days and 206.00 days, respectively. This indicated continued challenges in efficiently managing inventory and collecting receivables.
From December 2021 to December 2023, there was a consistent decrease in the cash conversion cycle, indicating improvement in the company's ability to convert its resources into cash more swiftly. By March 2024, the cash conversion cycle stood at 26.70 days, suggesting that Moderna Inc was more efficient in managing its working capital and converting it into cash by that time.
Overall, analyzing the cash conversion cycle data provides insights into Moderna Inc's operational efficiency and working capital management capabilities over the periods covered.